CN110066321A - 一种抗菌水凝胶及其制备方法和应用 - Google Patents
一种抗菌水凝胶及其制备方法和应用 Download PDFInfo
- Publication number
- CN110066321A CN110066321A CN201910342872.9A CN201910342872A CN110066321A CN 110066321 A CN110066321 A CN 110066321A CN 201910342872 A CN201910342872 A CN 201910342872A CN 110066321 A CN110066321 A CN 110066321A
- Authority
- CN
- China
- Prior art keywords
- hydrogel
- bacterial hydrogel
- bacterial
- antibacterial
- rada
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 45
- 239000000017 hydrogel Substances 0.000 title claims abstract description 43
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 239000003910 polypeptide antibiotic agent Substances 0.000 claims abstract description 11
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 6
- 241000191967 Staphylococcus aureus Species 0.000 claims abstract description 6
- 239000004471 Glycine Substances 0.000 claims abstract description 3
- 150000001413 amino acids Chemical group 0.000 claims description 12
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims description 7
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 4
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims 1
- 239000010931 gold Substances 0.000 claims 1
- 229910052737 gold Inorganic materials 0.000 claims 1
- 238000010532 solid phase synthesis reaction Methods 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 abstract description 5
- 238000003786 synthesis reaction Methods 0.000 abstract description 5
- 239000003242 anti bacterial agent Substances 0.000 abstract description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000011780 sodium chloride Substances 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 16
- 239000011347 resin Substances 0.000 description 16
- 229920005989 resin Polymers 0.000 description 16
- 238000000034 method Methods 0.000 description 10
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 6
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- 238000010511 deprotection reaction Methods 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 239000007790 solid phase Substances 0.000 description 5
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- -1 amino, amino Chemical group 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 150000003053 piperidines Chemical class 0.000 description 2
- 238000012805 post-processing Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 239000002121 nanofiber Substances 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000009938 salting Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Materials For Medical Uses (AREA)
- Oncology (AREA)
Abstract
本发明属于抗菌剂技术领域，具体涉及一种抗菌水凝胶及其制备方法和应用。通过两个甘氨酸(G)将短抗菌肽序列(AMP)与水凝胶序列(RADA)连接，得到抗菌水凝胶(AMP‑RADA)，其中，RADA在一定浓度的NaCl溶液中能形成稳定的水凝胶，AMP具有极好的抗菌效果，两者结合能够形成既具有水凝胶特性，又具有抗菌效果的抗菌水凝胶。本发明结构简单、合成方便、抗菌活性高，可用于金黄色葡萄球菌引起的疾病的预防和治疗。
Description
技术领域
本发明属于抗菌剂技术领域，具体涉及一种抗菌水凝胶及其制备方法和应用。
背景技术
多药耐药性细菌感染已成为人类健康的严重威胁，抗菌肽(AMP)是由少于50个氨基酸组成的阳离子两亲性肽，多种生物体能够产生，因为其优异的杀菌活性，对生物体本身的低细胞毒性，它们已被认为是抗生素的潜在替代品。
RADA是一种多肽，当暴露于生理介质或盐溶液时，其自发组装成稳定的二级结构并进一步形成有序的纳米结构，它在细胞培养，生物工程，纳米医学和其他领域具有潜在的应用价值。RADA水凝胶由大于99％的水组成，其中纳米纤维均匀分散，能够很好地模拟天然细胞外基质，为细胞培养和组织再生提供有利的3D微环境。
虽然抗菌肽具有良好的抗菌效果，但由于其易被酶水解的性质，导致其应用受到限制。因此将抗菌肽与水凝胶结合，形成一种抗菌水凝胶，对于抗菌肽的应用具有重要意义。
发明内容
本发明的目的在于为了解决现有技术中的不足，提供了一种结构简单，抗菌活性高的抗菌水凝胶及其合成方法和应用，本发明选择的抗菌肽序列与水凝胶序列结合能够很好地成胶，且制备的抗菌水凝胶具有较好的抗菌效果，在抑菌、杀菌领域均有广泛的应用前景。为了实现上述目的，本发明采用如下技术方案：
本发明的抗菌水凝胶由水凝胶和抗菌肽组成，抗菌水凝胶的全序列包括但不限于:GKRWWKWWRRGGRADARADARADARADA(AMP-RADA)。
其中，水凝胶的序列为：RADARADARADARADA(RADA)；
抗菌肽的序列为：GKRWWKWWRR(AMP)；
抗菌水凝胶的合成，采用固相化学合成法从C末端向N末端合成，具体制备方法步骤如下：
1、基本材料：
固相Fmoc法选择的树脂为Rink-Amide-ChemMatrix树脂，具有反应条件温和，副反应少，产率高等优点，采用HBTU和HOBt作为连接分子，将多肽分子固定到树脂上。
2、反应步骤
第一步，将第一个氨基酸共价连接到树脂上
加入适当的缩合剂如HBTU和HOBt，使被保护氨基酸羧基端与树脂形成共脂以完成氨基酸的固定；
第二步，去保护
采用碱性溶剂20％哌啶去除氨基上的Fmoc，暴露出氨基。
第三步，激活和交联
采用活化剂HBTU和HOBt活化下一个氨基上的羧基，与树脂上的氨基交联，形成肽键。
第四步，重复第二步和第三步，反复循环添加单体氨基酸，按照序列直到合成完成。
3、合成后处理
(1)洗脱和脱保护：脱保护基后，用切割液三氟乙酸(TFA)将肽链从树脂上切下来。
(2)HPLC分析纯化，冻干。
通过上述方法，合成多肽序列AMP-RADA。
所述抗菌肽通过两个甘氨酸(G)与水凝胶序列RADA连接起来，所述水凝胶序列包括但不限于RADA。
与现有技术相比，本发明具有以下有益效果：
(1)本发明制备得到的抗菌水凝胶对金黄色葡萄球菌具有持续、显著的抑制作用，还可以避免抗菌肽水解，可广泛应用于抑菌、杀菌领域中；
(2)本发明公开的制备工艺简单，结构稳定，反应温和，适合推广使用。
附图说明
图1为抗菌水凝胶的HPLC图。
图2为抗菌水凝胶AMP-RADA对金黄色葡萄球菌抗菌效果的测定曲线图。
图3为抗菌水凝胶AMP-RADA成胶实验图。
图4为抗菌水凝胶AMP-AMP-RADA成胶实验图。
具体实施方式：
以下结合实施例对本发明进行详细阐述，但这些实施例仅为例示说明之用，而不应被解释为对本发明实施的限制。
实施例1
本发明所述的方法采用常规的固相Fmoc法，即固相树脂上被Fmoc保护的单体氨基酸去保护后露出氨基，通过缩合反应与溶液中氨基酸的羧基形成肽键，从而将氨基酸连接到树脂上，使肽链从C端向N端延伸。
1、基本材料：
固相Fmoc法选择的树脂为Rink-Amide-ChemMatrix树脂，具有反应条件温和，副反应少，产率高等优点，采用HBTU和HOBt作为连接分子，将多肽分子固定到树脂上。
2、反应步骤
第一步，将第一个氨基酸共价连接到树脂上
加入适当的缩合剂如HBTU和HOBt，使被保护氨基酸羧基端与树脂形成共脂以完成氨基酸的固定；
第二步，去保护
采用碱性溶剂20％哌啶去除氨基上的Fmoc，暴露出氨基。
第三步，激活和交联
采用活化剂HBTU和HOBt活化下一个氨基上的羧基，与树脂上的氨基交联，形成肽键。
第四步，重复第二步和第三步，反复循环添加单体氨基酸，按照序列直到合成完成。
3、合成后处理
(1)洗脱和脱保护：脱保护基后，用切割液三氟乙酸(TFA)将肽链从树脂上切下来。
(2)HPLC分析纯化，冻干。
通过上述方法，合成多肽序列AMP-RADA。
4、抗菌效果测定
通过测定不同浓度抗菌水凝胶来反映其抗菌效果。首先将固定量被测多肽溶于蒸馏水中，得到一定浓度多肽溶液。实验中需用到金黄色葡萄球菌，首先将细菌放入TSB培养基中培养过夜，然后设置样品浓度进行涂板实验，根据最终细菌生长情况可以看出抗菌水凝胶对于金黄色葡萄球菌具有较好的抑制作用(图3)。
对比实施例1
采用常规的固相Fmoc法合成双链抗菌水凝胶
反复循环添加单体氨基酸，使肽链从C末端向N末端延伸，直到合成完成。其他步骤同实施例1。
该对比实施例得到的多肽不能形成水凝胶，具体见图4。
以上述依据本发明的理想实施例为启示，通过上述的说明内容，相关工作人员完全可以在不偏离本项发明技术思想的范围内，进行多样的变更及修改。本项发明的技术性范围并不局限于说明书上的内容，必须要根据权利要求范围来确定其技术范围。
Claims (5)
1.一种抗菌水凝胶，其特征在于，所述抗菌水凝胶由水凝胶和抗菌肽组成，抗菌水凝胶的氨基酸序列为:GKRWWKWWRRGGRADARADARADARADA(AMP-RADA)。
2.一种根据权利要求1所述的抗菌水凝胶的制备方法，其特征在于，所述抗菌水凝胶由Fmoc固相合成法制得。
3.根据权利要求2所述的抗菌水凝胶的制备方法，其特征在于，所述抗菌水凝胶通过HPLC进行分析、纯化。
4.根据权利要求2所述的抗菌水凝胶的制备方法，其特征在于，所述抗菌水凝胶通过两个甘氨酸(G)将抗菌肽与水凝胶序列连接起来。
5.一种根据权利要求1所述的抗菌水凝胶的应用，其特征在于，所述抗菌水凝胶用作金黄色葡萄球菌的抗菌药物。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910342872.9A CN110066321A (zh) | 2019-04-26 | 2019-04-26 | 一种抗菌水凝胶及其制备方法和应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910342872.9A CN110066321A (zh) | 2019-04-26 | 2019-04-26 | 一种抗菌水凝胶及其制备方法和应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110066321A true CN110066321A (zh) | 2019-07-30 |
Family
ID=67369111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910342872.9A Pending CN110066321A (zh) | 2019-04-26 | 2019-04-26 | 一种抗菌水凝胶及其制备方法和应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110066321A (zh) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110669147A (zh) * | 2019-10-24 | 2020-01-10 | 常州大学 | 一种用于Saureus菌检测的含明胶酶酶切序列的抗菌剂FAM-AMP |
| CN112321680A (zh) * | 2020-09-24 | 2021-02-05 | 南京斯泰尔医药科技有限公司 | 一种能够特异性识别并靶向S.aureus菌的抗菌肽 |
| CN112868668A (zh) * | 2021-03-19 | 2021-06-01 | 常州英诺升康生物医药科技有限公司 | 一种Fe3O4-DA-AMP纳米复合抗菌材料及其制备方法和应用 |
| CN113018507A (zh) * | 2021-04-02 | 2021-06-25 | 常州大学 | 一种具有光热性能的抗菌水凝胶及其制备方法和应用 |
| CN113384743A (zh) * | 2021-07-09 | 2021-09-14 | 吉林省国大生物工程有限公司 | 一种具有促进组织修复及抗菌的温敏敷料的制备方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106978406A (zh) * | 2017-04-07 | 2017-07-25 | 遵义医学院附属医院 | 一种具有酯酶活性的短肽自组装水凝胶及其应用 |
| CN107412150A (zh) * | 2017-07-16 | 2017-12-01 | 常州大学 | 一种用于包裹药物的多肽水凝胶的制备方法 |
| CN109456389A (zh) * | 2018-12-25 | 2019-03-12 | 苏州大学 | 一种抗菌肽、抗菌肽水凝胶及其制备方法 |
-
2019
- 2019-04-26 CN CN201910342872.9A patent/CN110066321A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106978406A (zh) * | 2017-04-07 | 2017-07-25 | 遵义医学院附属医院 | 一种具有酯酶活性的短肽自组装水凝胶及其应用 |
| CN107412150A (zh) * | 2017-07-16 | 2017-12-01 | 常州大学 | 一种用于包裹药物的多肽水凝胶的制备方法 |
| CN109456389A (zh) * | 2018-12-25 | 2019-03-12 | 苏州大学 | 一种抗菌肽、抗菌肽水凝胶及其制备方法 |
Non-Patent Citations (2)
| Title |
|---|
| GUOLI YANG ET AL.: "Sustained Release of Antimicrobial Peptide from Self-assembling Hydrogel Enhanced Osteogenesis", 《JOURNAL OF BIOMATERIALS SCIENCE, POLYMER EDITION》 * |
| 刘珊等: "阳离子抗菌肽融合细胞穿透肽增强其肿瘤细胞杀伤活性的实验研究", 《生物医学工程学杂志》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110669147A (zh) * | 2019-10-24 | 2020-01-10 | 常州大学 | 一种用于Saureus菌检测的含明胶酶酶切序列的抗菌剂FAM-AMP |
| CN112321680A (zh) * | 2020-09-24 | 2021-02-05 | 南京斯泰尔医药科技有限公司 | 一种能够特异性识别并靶向S.aureus菌的抗菌肽 |
| CN112868668A (zh) * | 2021-03-19 | 2021-06-01 | 常州英诺升康生物医药科技有限公司 | 一种Fe3O4-DA-AMP纳米复合抗菌材料及其制备方法和应用 |
| CN113018507A (zh) * | 2021-04-02 | 2021-06-25 | 常州大学 | 一种具有光热性能的抗菌水凝胶及其制备方法和应用 |
| CN113018507B (zh) * | 2021-04-02 | 2022-05-17 | 常州大学 | 一种具有光热性能的抗菌水凝胶及其制备方法和应用 |
| CN113384743A (zh) * | 2021-07-09 | 2021-09-14 | 吉林省国大生物工程有限公司 | 一种具有促进组织修复及抗菌的温敏敷料的制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110066321A (zh) | 一种抗菌水凝胶及其制备方法和应用 | |
| JP7267251B2 (ja) | 抗菌組成物及び医薬組成物 | |
| US9273095B2 (en) | Antibiotic peptide and preparation method therefor and application therefor | |
| CN101528248A (zh) | 抗微生物肽 | |
| CN101111256A (zh) | 抗菌肽及其使用方法 | |
| JPH08504837A (ja) | 新規ポリペプチドおよびこれから調製される抗ｈｉｖ剤 | |
| EP2213680A1 (en) | Peptides having pharmacological activity for treating disorders associated with altered cell migration, such as cancer | |
| US11680088B2 (en) | Bioactive peptides derived from snakes | |
| EP2625192A1 (en) | A bioactive amino acid sequence and use therefrom | |
| RU2010120571A (ru) | Тимус-специфический белок | |
| Wang et al. | Unnatural amino acids: Promising implications for the development of new antimicrobial peptides | |
| CA2524722A1 (en) | Acylated nonadepsipeptides | |
| JP2000217579A (ja) | 新規抗菌性ペプチド | |
| CN112646026B (zh) | 基于乳铁蛋白的仿生抗菌功能多肽及制备方法和应用 | |
| CN102766196B (zh) | 一组阳离子抗菌肽及其制备方法和应用 | |
| CN106188264A (zh) | 一种抗微生物肽Cm‑CATH3及其基因、制备方法和应用 | |
| JPH07501820A (ja) | 生物活性ペプチドおよびキレート剤による組成物および治療法 | |
| CA2451310C (en) | Antimicrobial peptides | |
| CN104327168A (zh) | 一种小分子多肽及其应用 | |
| EP3392263A1 (en) | Polypeptide compound, preparation method therefor and use thereof | |
| CN115925988B (zh) | 一种变性胶原靶向抗菌肽及其制备方法与应用 | |
| CN110028557B (zh) | 一种Ce6标记的双链抗菌肽及其合成方法和应用 | |
| CN104327165A (zh) | 一种多肽分子及其应用 | |
| JP4154218B2 (ja) | 新規抗菌性ポリペプチドとその利用 | |
| CN101024672A (zh) | 一种新型环状小肽ba及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190730 |